Movement Alert｜Corcept Therapeutics Rises 5.36% in Regular Trading, Cushing Syndrome NDA Resubmission and Earnings Expectations Boost Sentiment

Market Focus

Jul 24

On July 24, Corcept Therapeutics rose 5.36% in regular trading, trading at $95.755/share, with turnover of $25.46 million.

On the news front, the company has completed the resubmission of its New Drug Application for Relacorilant to treat Cushing's syndrome to the FDA, marking a critical milestone in the drug's path to market approval. This resubmission, initially announced in late May and completed in June, addresses prior regulatory feedback and aims to secure approval for this rare endocrine disorder treatment.

Additionally, the stock is benefiting from anticipation ahead of its upcoming earnings report scheduled for July 29. The company previously issued revenue guidance of $950 million to $1.05 billion, significantly above the FactSet consensus estimate of $899.5 million. Further supporting momentum, the FDA approved Lifyorli (relacorilant) combined with nab-paclitaxel for platinum-resistant ovarian cancer in March, with commercialization now underway.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1164135642"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1164135642\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1164135642?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-24 00:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1164135642","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Corcept Therapeutics Rises 5.36% in Regular Trading, Cushing Syndrome NDA Resubmission and Earnings Expectations Boost Sentiment","media":"Market Focus","content":"<p><p>On July 24, Corcept Therapeutics rose 5.36% in regular trading, trading at $95.755/share, with turnover of $25.46 million.</p><p>On the news front, the company has completed the resubmission of its New Drug Application for Relacorilant to treat Cushing's syndrome to the FDA, marking a critical milestone in the drug's path to market approval. This resubmission, initially announced in late May and completed in June, addresses prior regulatory feedback and aims to secure approval for this rare endocrine disorder treatment.</p><p>Additionally, the stock is benefiting from anticipation ahead of its upcoming earnings report scheduled for July 29. The company previously issued revenue guidance of $950 million to $1.05 billion, significantly above the FactSet consensus estimate of $899.5 million. Further supporting momentum, the FDA approved Lifyorli (relacorilant) combined with nab-paclitaxel for platinum-resistant ovarian cancer in March, with commercialization now underway.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Corcept Therapeutics Rises 5.36% in Regular Trading, Cushing Syndrome NDA Resubmission and Earnings Expectations Boost Sentiment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Corcept Therapeutics Rises 5.36% in Regular Trading, Cushing Syndrome NDA Resubmission and Earnings Expectations Boost Sentiment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-24 00:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 24, Corcept Therapeutics rose 5.36% in regular trading, trading at $95.755/share, with turnover of $25.46 million.</p><p>On the news front, the company has completed the resubmission of its New Drug Application for Relacorilant to treat Cushing's syndrome to the FDA, marking a critical milestone in the drug's path to market approval. This resubmission, initially announced in late May and completed in June, addresses prior regulatory feedback and aims to secure approval for this rare endocrine disorder treatment.</p><p>Additionally, the stock is benefiting from anticipation ahead of its upcoming earnings report scheduled for July 29. The company previously issued revenue guidance of $950 million to $1.05 billion, significantly above the FactSet consensus estimate of $899.5 million. Further supporting momentum, the FDA approved Lifyorli (relacorilant) combined with nab-paclitaxel for platinum-resistant ovarian cancer in March, with commercialization now underway.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CORT","symbol_name":"Corcept医疗","start_time":0,"source_url":"","article_id":"1164135642","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1164135642","pubTimestamp":1784822539,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 24, Corcept Therapeutics rose 5.36% in regular trading, trading at $95.755/share, with turnover of $25.46 million.On the news front, the company has completed the resubmission of its New Drug...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CORT":"Corcept医疗"},"translate_title":"走势警报|Corcept Therapeutics 常规交易上涨 5.36%，库欣综合征 NDA 重新提交和盈利预期提振情绪","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CORT":1},"content_text":"On July 24, Corcept Therapeutics rose 5.36% in regular trading, trading at $95.755/share, with turnover of $25.46 million.On the news front, the company has completed the resubmission of its New Drug Application for Relacorilant to treat Cushing's syndrome to the FDA, marking a critical milestone in the drug's path to market approval. This resubmission, initially announced in late May and completed in June, addresses prior regulatory feedback and aims to secure approval for this rare endocrine disorder treatment.Additionally, the stock is benefiting from anticipation ahead of its upcoming earnings report scheduled for July 29. The company previously issued revenue guidance of $950 million to $1.05 billion, significantly above the FactSet consensus estimate of $899.5 million. Further supporting momentum, the FDA approved Lifyorli (relacorilant) combined with nab-paclitaxel for platinum-resistant ovarian cancer in March, with commercialization now underway.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}